Chimeric antigen receptor–modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...

B-cell maturation antigen (BCMA) is widely expressed on the surface of mature B cells, normal and malignant plasma cells, but has low expression on other normal cells and no expression on CD34 + ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Chimeric antigen receptor (CAR) therapies utilize engineered receptors that are able to redirect immune cells to identify and destroy cancer cells that express a specific antigen. At present, CAR ...

This pivotal phase II, open-label study (ClinicalTrials.gov identifier: NCT03758417), conducted across eight sites in China, enrolled adult patients with RRMM who had received ≥ 3 lines of prior ...

Chimeric antigen receptors combine an antigen-recognition domain of a specific antibody with an intracellular domain of the CD3-zeta chain or FcγRI protein into a single chimeric protein. 1,2 ...